CARA - Cara Therapeutics EPS beats by $1.11 beats on revenue
Cara Therapeutics (CARA): Q4 GAAP EPS of $1.59 beats by $1.11.Revenue of $112.1M (+2391.1% Y/Y) beats by $63.47M.Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing unrestricted cash and cash equivalents and available-for-sale marketable securities as of December 31, 2020 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into 2023, without giving effect to any potential milestone payments or potential product revenue under existing collaborations.Press Release
For further details see:
Cara Therapeutics EPS beats by $1.11, beats on revenue